Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease

Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease

Christine M. Eng, Nathalie Guffon, William R. Wilcox et al. · New England Journal of Medicine · 2001 · 1.5K citations · Full text

Medicine, Clinical Sciences, Pharmacology +14

Carotid Wall Thickness is Predictive of Incident Clinical Stroke: The Atherosclerosis Risk in Communities (ARIC) Study

Lloyd E. Chambless, A.R. Folsom, Limin X. Clegg et al. · American Journal of Epidemiology · 2000 · 754 citations

Public Health, Preventive Medicine, Epidemiologic Methods +16

Elevated globotriaosylsphingosine is a hallmark of Fabry disease

Johannes M. F. G. Aerts, J.E.M. Groener, Sijmen Kuiper et al. · Proceedings of the National Academy of Sciences · 2008 · 727 citations · Full text

Life Sciences, Biochemistry, Pathology +14

SAFETY AND EFFICACY OF RECOMBINANT HUMAN a -GALACTOSIDASE A REPLACEMENT THERAPY IN FABRY'S DISEASE

Michelle Ng, N Athalie G Uffon, W Illiam R. W Ilcox et al. · 2001 · 482 citations

Life Sciences, Biochemistry, Clinical Sciences +5

Long-Term Safety and Efficacy of Enzyme Replacement Therapyfor Fabry Disease

William R. Wilcox, Maryam Banikazemi, Nathalie Guffon et al. · The American Journal of Human Genetics · 2004 · 405 citations · Full text

Life Sciences, Pharmacotherapy, Renal Replacement Therapy +7